Mesmor (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, preventing the synthesis of ergosterol, an essential component of the fungal cell membrane. This disruption impairs membrane integrity, inhibiting fungal growth and leading to cell death.

The dosing regimen for Mesmor is individualized and determined by the prescribing clinician based on the type and severity of the infection, patient weight, renal and hepatic function, and other clinical factors.

Safety data for itraconazole in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Mesmor, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

The primary alternative to itraconazole is voriconazole, another azole antifungal. While both target ergosterol synthesis, voriconazole often has broader spectrum activity against certain molds but may have a higher incidence of visual disturbances. Choice depends on infection type, susceptibility patterns, patient tolerance and drug‑interaction profile.

Mesmor must be stored at 2‑8 °C, kept refrigerated, protected from light, and should never be frozen or shaken. Before administration, allow the solution to reach room temperature if required, and follow aseptic techniques to maintain sterility.

Mesmor is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are set by the prescriber, typically over a period of 30 minutes to several hours, depending on the clinical protocol and patient tolerance.

Serious risks include hepatotoxicity, severe allergic reactions such as anaphylaxis, cardiac failure in susceptible individuals, visual disturbances, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for liver function, cardiac status and any signs of hypersensitivity.

Mesmor is contraindicated in patients with known hypersensitivity to itraconazole or any azole antifungal, those with uncontrolled heart failure, and individuals receiving strong CYP3A4 inducers that would render the therapy ineffective. Caution is also advised for patients with severe hepatic impairment.